MedTrace Logo

Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.

NCT01535443 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2019-10-16

Study results available
· View outcomes & findings →

Summary

Study to evaluate the safety and tolerability of PRO-155 Ophthalmic Solution 0.09 % in healthy volunteers.

Conditions

Interventions

DRUG

Bromfenac

Drug: Bromfenac Other names: PRO-155

Sponsors & Collaborators

  • Laboratorios Sophia S.A de C.V.

    lead INDUSTRY

Principal Investigators

  • Alfredo Lizarraga-Corona, MD · Unidad Medica "Grupo Pediátrico"

  • Leopoldo M Baiza-Duran, MD · Clinical Research Department. Laboratorios Sophia SA de CV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01535443 on ClinicalTrials.gov